JAK2 inhibitors in the treatment of myeloproliferative neoplasms

Raoul Tibes, James M. Bogenberger, Holly L. Geyer, Ruben Mesa

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Introduction: Dysregulation of JAK-STAT signaling is a pathogenetic hallmark of myeloproliferative neoplasms (MPNs) arising from several distinct molecular aberrations, including mutations in JAK2, the thrombopoietin receptor (MPL), mutations in negative regulators of JAK-STAT signaling, such as lymphocyte-specific adapter protein (SH2B3), and epigenetic dysregulation as seen with Suppressor of Cytokine Signaling (SOCS) proteins. In addition, growth factor/cytokine stimulatory events activate JAK-STAT signaling independent of mutations. Areas covered: The various mutations and molecular events activating JAK-STAT signaling in MPNs are reviewed. Detailed inhibitory kinase profiles of the currently developed JAK inhibitors are presented. Clinical trial results for currently developed JAK targeting agents are comprehensively summarized. The limitations of JAK-STAT targeting in MPNs, as well as potential rational combination therapies with JAK2 inhibitors, are discussed. Expert opinion: Aberrant JAK-STAT signaling is an underlying theme in the pathogenesis of MPNs. While JAK2 inhibitors are active in JAK2V617F and wild-type JAK2 MPNs, JAK2V617F mutation-specific or JAK2-selective inhibitors may possess unique clinical attributes. Complimentary targeting of parallel pathways operating in MPNs may offer novel therapeutic approaches in combination with JAK inhibition. Understanding the intricacies of JAK-STAT pathway activation, including growth factor/cytokine-driven signaling, will open new avenues for therapeutic intervention at known and novel molecular vulnerabilities of MPNs.

Original languageEnglish (US)
Pages (from-to)1755-1774
Number of pages20
JournalExpert Opinion on Investigational Drugs
Volume21
Issue number12
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Mutation
Neoplasms
Intercellular Signaling Peptides and Proteins
Thrombopoietin Receptors
Suppressor of Cytokine Signaling Proteins
Cytokines
Expert Testimony
Epigenomics
Phosphotransferases
Therapeutics
Clinical Trials
Lymphocytes
Proteins

Keywords

  • Acute leukemia
  • Essential thrombocythemia
  • JAK-STAT pathway
  • JAK2 inhibitors
  • Myeloproliferative neoplasms
  • Polycythemia vera, myelofibrosis
  • Primary myelofibrosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

JAK2 inhibitors in the treatment of myeloproliferative neoplasms. / Tibes, Raoul; Bogenberger, James M.; Geyer, Holly L.; Mesa, Ruben.

In: Expert Opinion on Investigational Drugs, Vol. 21, No. 12, 01.12.2012, p. 1755-1774.

Research output: Contribution to journalReview article

Tibes, Raoul ; Bogenberger, James M. ; Geyer, Holly L. ; Mesa, Ruben. / JAK2 inhibitors in the treatment of myeloproliferative neoplasms. In: Expert Opinion on Investigational Drugs. 2012 ; Vol. 21, No. 12. pp. 1755-1774.
@article{33b46b8894ef44da9151e52d92af421f,
title = "JAK2 inhibitors in the treatment of myeloproliferative neoplasms",
abstract = "Introduction: Dysregulation of JAK-STAT signaling is a pathogenetic hallmark of myeloproliferative neoplasms (MPNs) arising from several distinct molecular aberrations, including mutations in JAK2, the thrombopoietin receptor (MPL), mutations in negative regulators of JAK-STAT signaling, such as lymphocyte-specific adapter protein (SH2B3), and epigenetic dysregulation as seen with Suppressor of Cytokine Signaling (SOCS) proteins. In addition, growth factor/cytokine stimulatory events activate JAK-STAT signaling independent of mutations. Areas covered: The various mutations and molecular events activating JAK-STAT signaling in MPNs are reviewed. Detailed inhibitory kinase profiles of the currently developed JAK inhibitors are presented. Clinical trial results for currently developed JAK targeting agents are comprehensively summarized. The limitations of JAK-STAT targeting in MPNs, as well as potential rational combination therapies with JAK2 inhibitors, are discussed. Expert opinion: Aberrant JAK-STAT signaling is an underlying theme in the pathogenesis of MPNs. While JAK2 inhibitors are active in JAK2V617F and wild-type JAK2 MPNs, JAK2V617F mutation-specific or JAK2-selective inhibitors may possess unique clinical attributes. Complimentary targeting of parallel pathways operating in MPNs may offer novel therapeutic approaches in combination with JAK inhibition. Understanding the intricacies of JAK-STAT pathway activation, including growth factor/cytokine-driven signaling, will open new avenues for therapeutic intervention at known and novel molecular vulnerabilities of MPNs.",
keywords = "Acute leukemia, Essential thrombocythemia, JAK-STAT pathway, JAK2 inhibitors, Myeloproliferative neoplasms, Polycythemia vera, myelofibrosis, Primary myelofibrosis",
author = "Raoul Tibes and Bogenberger, {James M.} and Geyer, {Holly L.} and Ruben Mesa",
year = "2012",
month = "12",
day = "1",
doi = "10.1517/13543784.2012.721352",
language = "English (US)",
volume = "21",
pages = "1755--1774",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - JAK2 inhibitors in the treatment of myeloproliferative neoplasms

AU - Tibes, Raoul

AU - Bogenberger, James M.

AU - Geyer, Holly L.

AU - Mesa, Ruben

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Introduction: Dysregulation of JAK-STAT signaling is a pathogenetic hallmark of myeloproliferative neoplasms (MPNs) arising from several distinct molecular aberrations, including mutations in JAK2, the thrombopoietin receptor (MPL), mutations in negative regulators of JAK-STAT signaling, such as lymphocyte-specific adapter protein (SH2B3), and epigenetic dysregulation as seen with Suppressor of Cytokine Signaling (SOCS) proteins. In addition, growth factor/cytokine stimulatory events activate JAK-STAT signaling independent of mutations. Areas covered: The various mutations and molecular events activating JAK-STAT signaling in MPNs are reviewed. Detailed inhibitory kinase profiles of the currently developed JAK inhibitors are presented. Clinical trial results for currently developed JAK targeting agents are comprehensively summarized. The limitations of JAK-STAT targeting in MPNs, as well as potential rational combination therapies with JAK2 inhibitors, are discussed. Expert opinion: Aberrant JAK-STAT signaling is an underlying theme in the pathogenesis of MPNs. While JAK2 inhibitors are active in JAK2V617F and wild-type JAK2 MPNs, JAK2V617F mutation-specific or JAK2-selective inhibitors may possess unique clinical attributes. Complimentary targeting of parallel pathways operating in MPNs may offer novel therapeutic approaches in combination with JAK inhibition. Understanding the intricacies of JAK-STAT pathway activation, including growth factor/cytokine-driven signaling, will open new avenues for therapeutic intervention at known and novel molecular vulnerabilities of MPNs.

AB - Introduction: Dysregulation of JAK-STAT signaling is a pathogenetic hallmark of myeloproliferative neoplasms (MPNs) arising from several distinct molecular aberrations, including mutations in JAK2, the thrombopoietin receptor (MPL), mutations in negative regulators of JAK-STAT signaling, such as lymphocyte-specific adapter protein (SH2B3), and epigenetic dysregulation as seen with Suppressor of Cytokine Signaling (SOCS) proteins. In addition, growth factor/cytokine stimulatory events activate JAK-STAT signaling independent of mutations. Areas covered: The various mutations and molecular events activating JAK-STAT signaling in MPNs are reviewed. Detailed inhibitory kinase profiles of the currently developed JAK inhibitors are presented. Clinical trial results for currently developed JAK targeting agents are comprehensively summarized. The limitations of JAK-STAT targeting in MPNs, as well as potential rational combination therapies with JAK2 inhibitors, are discussed. Expert opinion: Aberrant JAK-STAT signaling is an underlying theme in the pathogenesis of MPNs. While JAK2 inhibitors are active in JAK2V617F and wild-type JAK2 MPNs, JAK2V617F mutation-specific or JAK2-selective inhibitors may possess unique clinical attributes. Complimentary targeting of parallel pathways operating in MPNs may offer novel therapeutic approaches in combination with JAK inhibition. Understanding the intricacies of JAK-STAT pathway activation, including growth factor/cytokine-driven signaling, will open new avenues for therapeutic intervention at known and novel molecular vulnerabilities of MPNs.

KW - Acute leukemia

KW - Essential thrombocythemia

KW - JAK-STAT pathway

KW - JAK2 inhibitors

KW - Myeloproliferative neoplasms

KW - Polycythemia vera, myelofibrosis

KW - Primary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84868711370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868711370&partnerID=8YFLogxK

U2 - 10.1517/13543784.2012.721352

DO - 10.1517/13543784.2012.721352

M3 - Review article

C2 - 22991927

AN - SCOPUS:84868711370

VL - 21

SP - 1755

EP - 1774

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -